Literature DB >> 17195884

Dementia: a brief review.

Hillel Grossman1, Christine Bergmann, Susan Parker.   

Abstract

Dementia is an increasingly common diagnosis in our aging population, and the numbers are expected to rise exponentially in coming years. Alzheimer's disease alone now affects 4.5 million people in the US, while millions more are currently affected by vascular dementia, Lewy Body disease and frontotemporal dementia. Each of these is a distinct entity, though overlapping symptoms and comorbidities occur frequently. Within the past two decades research has progressed rapidly on multiple fronts, including epidemiology, etiology, pathology, diagnosis and treatment. It is important for clinicians to recognize early signs and symptoms of dementia, and to note critical differences among them. Dementia research has moved beyond description of symptoms and clinicopathological correlation to the elucidation of risk factors, the pathobiology of the disease process, and most important, to the first generation of dementia treatments. Our purpose here is to review the current state of knowledge and directions of research for the four major dementias noted above. We are entering an era of dementia care that will be based upon the identification of potentially modifiable risk factors and early disease markers, and the application of new disease-specific diagnostic tools and treatment modalities.

Entities:  

Mesh:

Year:  2006        PMID: 17195884

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  9 in total

Review 1.  Huperzine A for vascular dementia.

Authors:  Zilong Hao; Ming Liu; Zhiqin Liu; Donghao Lv
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

2.  Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes.

Authors:  David Zade; Alexa Beiser; Regina McGlinchey; Rhoda Au; Sudha Seshadri; Carole Palumbo; Philip A Wolf; Charles Decarli; William Milberg
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-05-14       Impact factor: 2.136

3.  Effects of medication assessment as part of a comprehensive geriatric assessment on drug use over a 1-year period: a population-based intervention study.

Authors:  Pasi Lampela; Sirpa Hartikainen; Piia Lavikainen; Raimo Sulkava; Risto Huupponen
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

4.  Genetics of Vascular Dementia.

Authors:  Melissa E Murray; James F Meschia; Dennis W Dickson; Owen A Ross
Journal:  Minerva Psichiatr       Date:  2010-03

5.  Clinical features and multidisciplinary approaches to dementia care.

Authors:  Jacob Hg Grand; Sienna Caspar; Stuart Ws Macdonald
Journal:  J Multidiscip Healthc       Date:  2011-05-15

6.  Interleukin-8-251T > A, Interleukin-1α-889C > T and Apolipoprotein E polymorphisms in Alzheimer's disease.

Authors:  Alex Augusto Vendramini; Roger Willian de Lábio; Lucas Trevizani Rasmussen; Nathali Mattiuzo Dos Reis; Thais Minett; Paulo Henrique Ferreira Bertolucci; Marcela Augusta de Souza Pinhel; Dorotéia Rossi Silva Souza; Diego Robles Mazzotti; Marília de Arruda Cardoso Smith; Spencer Luiz Marques Payão
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

7.  Apolipoprotein ɛ4 breaks the association between declarative long-term memory and memory-based orienting of spatial attention in middle-aged individuals.

Authors:  Gerardo Salvato; Eva Z Patai; Tayla McCloud; Anna C Nobre
Journal:  Cortex       Date:  2016-06-13       Impact factor: 4.027

8.  Compensatory Postural Adjustments in an Oculus Virtual Reality Environment and the Risk of Falling in Alzheimer's Disease.

Authors:  Miguel F Gago; Darya Yelshyna; Estela Bicho; Hélder David Silva; Luís Rocha; Maria Lurdes Rodrigues; Nuno Sousa
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-06-25

Review 9.  The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.

Authors:  Parveen Salahuddin; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Cell Mol Biol Lett       Date:  2014-08-20       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.